Merck to Acquire IOMet Pharma

800px-merck_logo-svgMerck has agreed to pay up to $400 million to acquire IOmet Pharma, a Scottish company that specializes in the development of small molecule-based cancer treatments.

IOmet will operate as a division of Merck. The acquisition will include IOmet’s pre-clinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors.


This entry was posted in Pharmaceutical Trademarks, Pharmaceuticals, Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s